Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Tonix Pharma ( (TNXP) ) is now available.
On March 3, 2025, Tonix Pharmaceuticals presented data at the 7th International Congress on Controversies in Fibromyalgia, highlighting the effectiveness of their transmucosal sublingual cyclobenzaprine (TNX-102 SL) in reducing pain associated with fibromyalgia through improved non-restorative sleep. This presentation underscores Tonix’s commitment to addressing fibromyalgia and strengthens its position in the pharmaceutical industry by showcasing successful results from two Phase 3 studies.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing therapies for central nervous system disorders, immunology, and infectious diseases. The company is known for its work on fibromyalgia treatments and other related conditions.
YTD Price Performance: -76.17%
Average Trading Volume: 1,627,104
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $43.94M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.